A phase I study of vernakalant (Brinavess) in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2016
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- 10 Mar 2016 Status changed from planning to recruiting according to Cardiome Pharma media release.
- 29 Jul 2015 New trial record
- 24 Jul 2015 According to a Cardiome Pharma media release, this study will support the regulatory approval of vernakalant [BRINAVESS] in China. If BRINAVESS successfully completes Phase I, Eddingpharm anticipates initiating a pivotal Phase 3 study by year end.